Lilly (Eli) & Co (LLY)
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products and other therapies. Co.'s diabetes products include: Basaglar®, a long-acting human insulin analog for the treatment of diabetes; and Trajenta®, for the treatment of type 2 diabetes. Co.'s oncology products include: Alimta®, for treatment of patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.
Eli Lilly SEC Filing Email Alerts Service
Company Name: |
Lilly (Eli) & Co |
Stock buyback: |
LLY buyback |
Website: |
www.lilly.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding LLY: |
121 |
Total Market Value Held by ETFs: |
$78.45B |
Total Market Capitalization: |
$739.40B |
% of Market Cap. Held by ETFs: |
10.61% |
|
|
March 29, 2024 12:00 PM Eastern
Strong Buy (3.79 out of 4)
71st percentile
|
|